Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...
On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback